[
    [
        {
            "time": "",
            "original_text": "正大天晴安罗替尼获批 肺癌靶向药市场谁是强者？",
            "features": {
                "keywords": [
                    "安罗替尼",
                    "获批",
                    "肺癌",
                    "靶向药",
                    "市场"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "正大天晴安罗替尼获批 肺癌靶向药市场谁是强者？",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业17年报18年一季报总结:增速回升,内部分化,关注创新、优质仿制药、连锁药店、医药商业",
            "features": {
                "keywords": [
                    "医药生物",
                    "年报",
                    "季报",
                    "增速回升",
                    "内部分化",
                    "创新",
                    "仿制药",
                    "连锁药店",
                    "医药商业"
                ],
                "sentiment_score": 0.65,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业17年报18年一季报总结:增速回升,内部分化,关注创新、优质仿制药、连锁药店、医药商业",
                "Correlation": 6,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 8,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        }
    ]
]